{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T10:30:55Z","timestamp":1787135455178,"version":"build-2736575974"},"reference-count":30,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Evaluate safety and efficacy of AGN-241622 ophthalmic solution in healthy individuals and individuals with presbyopia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This vehicle-controlled, participant- and investigator-masked, randomized phase 1\/2 study enrolled healthy individuals and individuals with presbyopia, aged 40\u201365 years, at 10 sites in the US from 30 July 2020 to 05 Dec 2022 (NCT04403763). Stage 1 cohorts were randomized (3:1) sequentially to receive AGN-241622 (0.01%, 0.03%, or 0.1% ophthalmical solution) or vehicle once in the left eye. Stage 2a cohorts were randomized (3:1) sequentially to receive AGN-241622 (0.01%, 0.03%, or 0.1%) or vehicle daily in both eyes for 14 days. Safety included treatment-emergent adverse events (TEAEs). Efficacy included change in pupil diameter and high-contrast, binocular distance-corrected near visual acuity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 80 participants were randomized to AGN-241622 (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 61) or vehicle (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 19), and 76 completed the study; baseline characteristics were well balanced. All TEAEs were of mild severity. All but 1 TEAE (not related to AGN-241622) resolved. In Stage 1, the most frequently reported ocular TEAE was increased lacrimation (AGN-241622 0.01% [\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 4], AGN-241622 0.03% [\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 1], and vehicle [\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 1]). In Stage 2a, there were 2 TEAEs of mild severity (dermatitis) in 1 participant who received AGN-241622 0.1% that led to discontinuation, which resolved and was unrelated to AGN-241622. Modest efficacy in pupil reduction and vision improvement was also observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>AGN-241622 ophthalmic solution was well tolerated, and modest efficacy was observed in binocular distance-corrected near visual acuity in presbyopic participants with the drug concentrations assessed in this study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10807683251396381","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T01:09:35Z","timestamp":1763428175000},"page":"21-29","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Efficacy of AGN-241622 for Presbyopia: Results From a First-in-Human, Phase 1\/2, Randomized, Vehicle-Controlled Study"],"prefix":"10.1177","volume":"42","author":[{"given":"Sherif M.","family":"El-Harazi","sequence":"first","affiliation":[{"name":"Global Research Management, Glendale, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Peace","sequence":"additional","affiliation":[{"name":"United Medical Research Institute, Inglewood, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Allergan, an AbbVie Company, North Chicago, IL, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Yuan","sequence":"additional","affiliation":[{"name":"Allergan, an AbbVie Company, North Chicago, IL, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Lee","sequence":"additional","affiliation":[{"name":"Allergan, an AbbVie Company, North Chicago, IL, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Robinson","sequence":"additional","affiliation":[{"name":"Allergan, an AbbVie Company, North Chicago, IL, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wirta","sequence":"additional","affiliation":[{"name":"Eye Research Foundation, Newport Beach, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2024.102157"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.04.013"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40135-018-0190-3"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-017-0068-8"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-306663"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-017-0090-x"},{"key":"e_1_3_5_8_2","volume-title":"Optometric clinical practice guideline: care of the patient with presbyopia","author":"American Optometric Association","unstructured":"American Optometric Association. Optometric clinical practice guideline: care of the patient with presbyopia. AOA."},{"issue":"6","key":"e_1_3_5_9_2","first-page":"370","article-title":"Impact of presbyopia and its correction in low- and middle-income countries","volume":"7","author":"Chan VF","year":"2018","unstructured":"Chan VF, , MacKenzie GE, , Kassalow J, et al. Impact of presbyopia and its correction in low- and middle-income countries. Asia Pac J Ophthalmol (Phila), 2018; 7(6):370\u2013374; doi: 10.22608\/apo.2018449","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.12954"},{"key":"e_1_3_5_11_2","unstructured":"WHO. WorldReport on Vision. Available from: https:\/\/www.who.int\/docs\/defaultsource\/documents\/world-vision-report-post-launch-accessible.pdf?sfvrsn=1b29f0e7_2"},{"issue":"7","key":"e_1_3_5_12_2","first-page":"25","article-title":"Presbyopia Treatment With Eye Drops: An Eight Year Retrospective Study","volume":"9","author":"Benozzi G","year":"2020","unstructured":"Benozzi G, , Perez C, , Leiro J, et al. Presbyopia Treatment With Eye Drops: An Eight Year Retrospective Study. Transl Vis Sci Technol, 2020; 9(7):25.","journal-title":"Transl Vis Sci Technol"},{"key":"e_1_3_5_13_2","first-page":"3","article-title":"Presbyopia: A new potential pharmacological treatment","volume":"1","author":"Benozzi J","year":"2012","unstructured":"Benozzi J, , Benozzi G, , Orman B. Presbyopia: A new potential pharmacological treatment. M\u00e9d Hypothesis, Discov Innov Ophthalmol J, 2012; 1:3\u20135.","journal-title":"M\u00e9d Hypothesis, Discov Innov Ophthalmol J"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1532-5415.2002.50502.x"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2018.09.004"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-022-01002-4"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.3928\/1081597X-20191010-04"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2022.0059"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/j.jcrs.0000000000001313"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1544241"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2023.101225"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11051385"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2023.12.005"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-016-0065-3"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.121.11.1577"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-3294"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.06-0586"},{"issue":"9","key":"e_1_3_5_28_2","first-page":"1446","article-title":"Comparison of FDA safety and efficacy data for KAMRA and Raindrop corneal inlays","volume":"10","author":"Moshirfar M","year":"2017","unstructured":"Moshirfar M, , Desautels JD, , Wallace RT, et al. Comparison of FDA safety and efficacy data for KAMRA and Raindrop corneal inlays. Int J Ophthalmol, 2017; 10(9):1446\u20131451.","journal-title":"Int J Ophthalmol"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.3928\/1081597X-20090917-05"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000864"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.3928\/1081597X-20210408-06"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10807683251396381","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10807683251396381","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10807683251396381","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T10:21:24Z","timestamp":1787134884000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10807683251396381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"alternative-id":["10.1177\/10807683251396381"],"URL":"https:\/\/doi.org\/10.1177\/10807683251396381","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]}}}